Agenus Expands BOT+BAL Data with ESMO 2026 Presentations Across Multiple Cancer Types
Event summary
- Three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) accepted for ESMO 2026.
- Presentations span neoadjuvant colorectal cancer, refractory metastatic colorectal cancer, and advanced sarcoma.
- NEOASIS study presents updated data on neoadjuvant dMMR colorectal cancer cohort.
- Real-world data from Spanish expanded access program and multicenter AGEO study to be presented.
The big picture
Agenus continues to expand the clinical footprint of its BOT+BAL combination, with ESMO 2026 presentations highlighting investigator interest across diverse tumor types and treatment settings. The focus on neoadjuvant approaches and heavily pretreated patients underscores the strategic push to differentiate in both early and late-line immuno-oncology applications.
What we're watching
- Clinical Validation
- Whether the NEOASIS study data will support broader neoadjuvant applications for BOT+BAL in colorectal cancer.
- Market Differentiation
- How real-world data from refractory and advanced sarcoma settings positions Agenus against competitors.
- Regulatory Pathways
- The pace at which investigator-led data may influence future regulatory filings or approval strategies.
Related topics